SVRA - Savara Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Savara Inc.

Building 3
Suite 200 6836 Bee Cave Road
Austin, TX 78746
United States
512-961-1891
http://www.savarapharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees41

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert NevilleCo-Founder, Exec. Chairman & CEO772.75k995.54k1966
Dr. Jaakko Taneli JouhikainenPres & COO751.09kN/A1966
Mr. David L. LowranceCFO & Sec.503.89k426.1k1968
Ms. Anne EricksonVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Kate McCabeVP of Legal AffairsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; and in Phase IIa development stage for treating nontuberculous mycobacterial lung infection. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquartered in Austin, Texas.

Corporate Governance

Savara Inc.’s ISS Governance QualityScore as of July 29, 2019 is 3. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.